Daratumumab after allogeneic hematopoietic cell transplantation for multiple myeloma is safe and synergies with pre-existing chronic graft versus host disease. A retrospective study from the CMWP EBMT.
Laure VincentLuuk GrasPatrice CeballosJürgen FinkeJakob PasswegStéphanie HarelLaura RosinolMonique C MinnemaRaphael TeipelJaap A van DoesumMathias HänelPascal LenainCarmen Botella-GarciaChristian KoeneckeSophie DucastelleJaime Sanz CaballerWilfried SchroyensTsila ZukermanFederico MonacoLinda KosterLiesbeth de WreedePatrick J HaydenStefan O SchönlandIbrahim Yakoub AghaMeral BeksacPublished in: Bone marrow transplantation (2022)